CRNX shows severe cash burn acceleration with operating cash outflow increasing 67% to $378M while cash reserves plummeted 62% to $101M, creating potential liquidity concerns.
The company is burning through cash at an alarming rate with only $101M remaining versus $377M in annual operating cash outflow, suggesting less than four months of runway at current burn rates. The 92% spike in SG&A expenses alongside increased R&D spending indicates the company is in heavy investment mode but with dramatically reduced financial cushion.
CRNX experienced a dramatic deterioration across all financial metrics, with revenue declining 74% to just $1M while operating losses expanded 53% to $517M driven by explosive 92% growth in SG&A expenses and 38% increase in R&D spending. The company's cash position collapsed 62% to $101M while operating cash burn accelerated 67% to $378M annually, creating an immediate liquidity crisis. The overall picture signals a biotech company in late-stage development burning cash at an unsustainable rate with severely limited financial runway.
SG&A up 91.8% — significant increase in sales or administrative costs, monitor impact on operating leverage.
Revenue declined 74.1% — significant demand weakness or market share loss warrants investigation.
Operating cash flow fell 67.2% — earnings quality concerns; investigate working capital changes and non-cash items.
Cash declined 61.6% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Net income declined 55.9% — review whether driven by operations, interest costs, or non-recurring items.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Capital expenditure jumped 49.9% — major investment cycle underway; assess returns on deployment.
Current liabilities surged 42.5% — significant near-term obligations; verify ability to meet short-term debt.
R&D investment increased 38.3% — signals commitment to future product development, though near-term margin impact.
Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →